Literature DB >> 8851592

Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa.

D M Cappelletty1, M J Rybak.   

Abstract

The purpose of this study was to determine if synergism was maintained for various combinations of beta-lactams with an aminoglycoside against four clinical strains and one laboratory strain of Pseudomonas aeruginosa which were resistant, according to the MICs, to the beta-lactams and/or aminoglycoside. The results from both the checkerboard and killing curve methodologies were compared. The laboratory strain (ATCC 27853) was manipulated in vitro by serial passage onto agar containing increasing concentrations of each antibiotic to select for resistance. One clinical isolate (R61) was also serially passed to raise the MIC of piperacillin from 128 to 1,024 micrograms/ml. The fractional inhibitory concentration indices for all isolates indicated indifference for all combination therapies, with values ranging from 0.6 to 3. In contrast, killing curve results for all isolates demonstrated synergism with drug concentrations at either one-fourth or one-half the MIC for each organism. The MIC of piperacillin for the laboratory-manipulated clinical isolate R61 was 1,024 micrograms/ml, and synergism was still observed with concentrations of one-half the MIC of piperacillin and amikacin. For clinical isolate R166, which was beta-lactam and tobramycin resistant, synergism continued to be demonstrated with concentrations of tobramycin (1/16 MIC) in combination with piperacillin and cefepime at 1/2 the MIC. The results of this study indicate that against P. aeruginosa, synergism is observed in spite of resistance to beta-lactams and/or aminoglycosides. Synergism appears to be maintained even at very high MICs (piperacillin, 1,024 micrograms/ml; tobramycin, 128 micrograms/ml) with drug concentrations within achievable therapeutic ranges. With current definitions of synergism there was a complete lack of correlation between the results obtained by the checkerboard and killing curve methodologies, with the fractional inhibitory concentration indices showing indifference and killing curves resulting in synergism. The methodologies and definitions of synergism or antagonism are variable and not standardized and should be reevaluated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8851592      PMCID: PMC163179     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Effect of increasing doses of amikacin with or without piperacillin in the serum bactericidal test.

Authors:  H Lagast; A Pascual-Lopez; P Dejace; J Klastersky
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

2.  Early synergistic interactions between amikacin and six beta-lactam antibiotics against multiply resistant members of the family Enterobacteriaceae.

Authors:  R H Glew; R A Pavuk
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

3.  Problems in determination of antibiotic synergism in vitro.

Authors:  C W Norden
Journal:  Rev Infect Dis       Date:  1982 Mar-Apr

4.  Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine.

Authors:  W R Greco; H S Park; Y M Rustum
Journal:  Cancer Res       Date:  1990-09-01       Impact factor: 12.701

5.  Comparison of the activity of antibiotic combinations in vitro with clinical outcome and resistance emergence in serious infection by Pseudomonas aeruginosa in non-neutropenic patients.

Authors:  P H Chandrasekar; L R Crane; E J Bailey
Journal:  J Antimicrob Chemother       Date:  1987-03       Impact factor: 5.790

6.  Early effects of beta-lactams on aminoglycoside uptake, bactericidal rates, and turbidimetrically measured growth inhibition in Pseudomonas aeruginosa.

Authors:  M H Miller; S A Feinstein; R T Chow
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

7.  Synergy of new C-3 substituted cephalosporins and tobramycin against Pseudomonas aeruginosa and Pseudomonas cepacia.

Authors:  N X Chin; H C Neu
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Jul-Aug       Impact factor: 2.803

8.  Time-kill studies and synergy testing of broad-spectrum antibiotics against blood culture isolates.

Authors:  M Arpi
Journal:  Chemotherapy       Date:  1988       Impact factor: 2.544

9.  Involvement of the outer membrane in gentamicin and streptomycin uptake and killing in Pseudomonas aeruginosa.

Authors:  R E Hancock; V J Raffle; T I Nicas
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

10.  Effect of highly potent antipseudomonal beta-lactam agents alone and in combination with aminoglycosides against Pseudomonas aeruginosa.

Authors:  S A Lerner; E J Dudek; W E Boisvert; K D Berndt
Journal:  Rev Infect Dis       Date:  1984 Sep-Oct
View more
  29 in total

1.  In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.

Authors:  Michael T Sweeney; Gary E Zurenko
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

Review 2.  Current concepts in laboratory testing to guide antimicrobial therapy.

Authors:  Stephen G Jenkins; Audrey N Schuetz
Journal:  Mayo Clin Proc       Date:  2012-03       Impact factor: 7.616

3.  Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.

Authors:  Glenn A Pankuch; Gengrong Lin; Harald Seifert; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-10-29       Impact factor: 5.191

4.  Activity of levofloxacin alone and in combination with a DnaK inhibitor against gram-negative rods, including levofloxacin-resistant strains.

Authors:  Kim Credito; Gengrong Lin; Laura Koeth; Michael A Sturgess; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

5.  Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology.

Authors:  M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

6.  Synergy of drug combinations in treating multidrug-resistant Pseudomonas aeruginosa.

Authors:  Meher Rizvi; Junaid Ahmad; Fatima Khan; Indu Shukla; Abida Malik; Hiba Sami
Journal:  Australas Med J       Date:  2015-01-31

Review 7.  When does 2 plus 2 equal 5? A review of antimicrobial synergy testing.

Authors:  Christopher D Doern
Journal:  J Clin Microbiol       Date:  2014-06-11       Impact factor: 5.948

8.  Activities of antibiotic combinations against resistant strains of Pseudomonas aeruginosa in a model of infected THP-1 monocytes.

Authors:  Julien M Buyck; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

9.  Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan.

Authors:  Po-Ren Hsueh; Lee-Jene Teng; Cheng-Yi Chen; Wen-Hwei Chen; Chong-Jen Yu; Shen-Wu Ho; Kwen-Tay Luh
Journal:  Emerg Infect Dis       Date:  2002-08       Impact factor: 6.883

10.  In Vitro Synergy of Levofloxacin Plus Piperacillin/Tazobactam against Pseudomonas aeruginosa.

Authors:  Vladimir Chachanidze; Aixa Curbelo-Irizarry; Deborah Ashcraft; George Pankey
Journal:  Interdiscip Perspect Infect Dis       Date:  2009-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.